DOCSLIB.ORG

LUPIN-2011-2012.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LUPIN-2011-2012.Pdf Spine has to be adjusted by printer at his end BUILT TO GROW ANNUAL REPORT 2012 LUPIN Spine has to be adjusted by printer at his end Spine has to be adjusted by printer at his end 1st 3rd 9th 14th Largest Indian Largest Indian Largest Largest generic pharmaceutical pharmaceutical Japanese pharmaceutical company in the company generic company USA by pharmaceutical globally prescriptions company An innovation led transnational pharmaceutical company LUPIN LIMITED Corporate Office Laxmi Towers, ‘B’ Wing, Bandra Kurla Complex Bandra (East) LUPIN 2012 Mumbai 400 051 India Tel: +91 (22) 6640 2222 > USD 1.4 billion revenue Registered Office > 20% EBITDA and growing 159, C.S.T. Road, Kalina Santacruz (East) Expanding global footprint Mumbai 400 098 India Tel: +91 (22) 6640 2323 Market capitalization has grown 11 times in 7 years Email Within reach of top 25 global pharmaceutical companies [email protected] Website www.lupinworld.com Spine has to be adjusted by printer at his end BUILT TO GROW Lupin was founded in 1968 with the vision to develop new drugs to combat and eradicate life-threatening diseases. To manufacture drugs of the highest social priority so as to nurture, protect and enrich our society. Embedded in Lupin was a formula for growth. Forty-four years on, what has stayed with us is that same entrepreneurial spirit, culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people. We are today a fully integrated pharmaceutical company with an unrivaled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With the building blocks in place, the future looks brighter than its ever been. We are Built to Grow. CHAIRMAN’S MESSAGE Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation Dr Desh Bandhu Gupta Founder and Chairman 02 BUILT TO GROW My Dear Shareowners When I started Lupin over 40 years ago, the dream was simple – to provide as many people as possible with affordable medicines that would address the most prevalent diseases of the highest social priority, such as tuberculosis. I discovered that by working hard on a noble ambition, growth and success followed. Embedded in Lupin is a formula for this growth. Growth fuelled by a boundless vision, the determination to succeed and reach for our dreams. These fundamental philosophies are what drive Lupin - creativity, performance and innovation. Lupin has delivered the highest growth performance consistently over the past ten years. We expect the future to be no different and we continue to invest in new therapy areas, reach out to new territories and dive deeper into our existing markets. As we have grown as a company, we realized that our ambitions were bigger than generic products alone and that we had the means to go up the value chain into specialty products and proprietary research and development. That is the journey we are on today – to become a global specialty pharmaceutical company offering a wide portfolio of generic and proprietary products. As always, it is a pleasure for me to address you and to share our results for the previous year. We have carefully put together all the pieces of our story, to be counted amongst the leading pharmaceutical companies in the world. Lupin is Built to Grow. With Best Wishes Dr Desh Bandhu Gupta Founder and Chairman Lupin Limited 03 LUPIN Annual Report 2012 CONTENTS 02 Chairman’s Message 06 Corporate Information 07 Board of Directors 08 Financial Highlights 10 Managing Director’s Letter 14 US & Europe 18 India 22 Rest of the World 25 Active Pharmaceutical Ingredients 26 Research & Development 32 Manufacturing 33 Quality & Regulatory Compliance 36 Human Resources 38 Financial Review 42 Corporate Social Obligation 44 Built As One 46 Six Year Financial Summary 48 Reports And Accounts Shakti Chakraborty Naresh Gupta Divakar Kaza Vinod Dhawan 04 MANAGEMENT TEAM Ramesh Swaminathan Ms Vinita Gupta Dr Desh Bandhu Gupta Dr Kamal K Sharma Nilesh Gupta 05 LUPIN Annual Report 2012 CORPORATE INFORMATION DIRECTORS SENIOR MANAGEMENT TEAM REGISTERED OFFICE Dr Desh Bandhu Gupta Dr Desh Bandhu Gupta 159, C.S.T. Road, Kalina Chairman Chairman Santacruz (East) Dr Kamal K Sharma Dr Kamal K Sharma Mumbai 400 098 Managing Director Managing Director Tel:+ 91 22 6640 2323 Mrs M D Gupta Fax:+ 91 22 2652 8806 Executive Director Ms Vinita Gupta Group President & CEO - Mr Nilesh Gupta Lupin Pharmaceuticals Inc., USA CORPORATE OFFICE Executive Director Laxmi Towers, 'B' Wing Ms Vinita Gupta Mr Nilesh Gupta Bandra Kurla Complex Dr Vijay Kelkar Group President & Executive Director Bandra (East) Mr Richard Zahn Mr Shakti Chakraborty Mumbai 400 051 Mr R A Shah Group President - Dr K U Mada India Region Formulations & CIS Tel: + 91 22 6640 2222 Mr D K Contractor Fax: + 91 22 6640 2130 Mr Vinod Dhawan Group President - www.lupinworld.com COMPANY SECRETARY & AAMLA & Business Development COMPLIANCE OFFICER E-Mail Mr R V Satam Mr Ramesh Swaminathan President - Finance & Planning [email protected] AUDITORS Dr Rajender Kamboj Deloitte Haskins & Sells President - Novel Drug Discovery & Chartered Accountants Development AUDIT COMMITTEE Mr Naresh Gupta President - API & Global TB Dr K U Mada Chairman Dr Kamal K Sharma Mr Divakar Kaza Mr D K Contractor President - Human Resources Mr Alok Ghosh INVESTORS' GRIEVANCES President - Technical Operations COMMITTEE Mr D K Contractor Chairman Dr Cyrus Karkaria President - Biotechnology Dr K U Mada Mr Sunil Makharia REMUNERATION Executive Vice President - Finance COMMITTEE Mr Debabrata Chakravorty Dr K U Mada Chairman Executive Vice President - Supply Mr R A Shah Planning & Strategic Sourcing SOLICITORS Mr Andrew Macaulay Crawford Bayley & Co. Executive Vice President - Lupin (Europe) Ltd. BANKERS Dr Dhananjay Bakhle Central Bank of India Executive Vice President - Bank of Baroda Medical Research State Bank of India Dr Sofia Mumtaz Citibank N.A. Executive Vice President - IPMG The Hongkong and Shanghai Banking Corporation Limited Mr Rajendra Chunodkar Standard Chartered Bank Executive Vice President - Technical ICICI Bank Limited Mr R S Raghav Kotak Mahindra Bank Limited Executive Vice President - J P Morgan Chase Bank N.A. Marketing & Sales 06 BOARD OF DIRECTORS Dr Desh Bandhu Gupta Chairman Dr Kamal K Sharma Managing Director Mrs M D Gupta Executive Director Mr Nilesh Gupta Executive Director Ms Vinita Gupta Dr Vijay Kelkar Mr Richard Zahn Mr R A Shah Dr K U Mada Mr D K Contractor AWARDS 2011-12 Ernst & Young Entrepreneur of the Year Life Sciences and Health Care – Dr Desh Bandhu Gupta NDTV Business Leadership Awards Pharmaceutical Company of the Year Business Today 30 Most Powerful Women in Business Ms Vinita Gupta 06 Business Today Yes Bank Best CFO Awards Best Leverage Management – Large Companies Mr Ramesh Swaminathan 07 LUPIN Annual Report 2012 FINANCIAL HIGHLIGHTS 2012 Revenue Composition (%) Net Sales 69,597 (` million) 57,068 47,736 API Domestic Formulations 37,950 Advanced Markets Emerging Markets 28,341 Formulations Formulations 12 27 FY 08 FY 09 FY 10 FY 11 FY 12 52 9 Profit Before Tax 11,960 (` million) 9,963 14,590 EBITDA 8,357 (` million) 12,000 6,060 5,402 9,981 7,439 6,423 FY 08 FY 09 FY 10 FY 11 FY 12 FY 08 FY 09 FY 10 FY 11 FY 12 Exports (` million) 41,862 Consolidated Net Profit Formulation 32,955 (` million) 8676 API 26,405 8,626 19,654 6,816 5,015 10,032 4,083 5,260 5,047 5,562 5,931 6,434 FY 08 FY 09 FY 10 FY 11 FY 12 FY 08 FY 09 FY 10 FY 11 FY 12 08 Cumulative Capex Cumulative R&D (` million) 20,609 (` million) 20,067 5,514 5,940 15,095 14,127 4,808 5,301 10,287 8,826 4,433 4,119 5,854 4,707 3,489 2,669 2,345 2,038 2,365 2,038 FY 08 FY 09 FY 10 FY 11 FY 12 FY 08 FY 09 FY 10 FY 11 FY 12 Geographic Break Down (%) Contribution Domestic Exports - Advanced Market Exports - Emerging Market Dividend 160 (%) 150 35 33 32 31 45 135 125 35 47 50 51 53 100 20 18 17 17 16 FY 08 FY 09 FY 10 FY 11 FY 12 FY 08 FY 09 FY 10 FY 11 FY 12 Lupin Share price movement (`) Closing Rate (BSE) Closing Rate (NSE) 600.00 529.5 500.00 529.65 400.00 Earning Per Share Basic 19.43 (`) 19.36 300.00 200.00 15.84 12.17 100.00 12.53 10.00 0.00 12.53 * 31.03.03 * 31.03.04 * 31.03.05 * 31.03.06 * 31.03.07 * 31.03.08 * 31.03.09 * 31.03.10 * 31.03.11 * 31.03.12 FY 08 FY 09 FY 10 FY 11 FY 12 09 LUPIN Annual Report 2012 MANAGING DIRECTOR’S LETTER Our culture drives us to reach for superior goals, higher productivity and sound business practices; this discipline has made us the 14th largest generic player in the world Dr Kamal K Sharma Managing Director 10 THE CULTURE TO GROW Dear Shareholders We have now recorded 7 consecutive years of consistent growth. The momentum built through this journey reassures that our businesses are on the desired track of consistent and sustainable growth. It is our culture that challenges us to reach for superior goals, higher productivity and ever more meticulous business practices. We are now the 14th largest generic pharmaceutical company in the world by revenues; we remain the 5th largest and fastest growing generics player in the US.
Load more

Recommended publications
  • Pharma Limited. Lupin Limited, Lupin
    Case 8:15-cv-03437-GJH Document 1 Filed 11/10/15 Page 1 of 17 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND SHIRE PHARMACEUTICAL DEVELOPMENT INC., SHIRE DEVELOPMENT LLC, COSMO TECHNOLOGIES LIMITED, and NOGRA Civil Action No. PHARMA LIMITED. Plaintiffs, v. LUPIN LIMITED, LUPIN PHARMACEUTICALS INC., LUPIN INC., and LUPIN ATLANTIS HOLDINGS SA Defendants. COMPLAINT Plaintiffs Shire Pharmaceutical Development Inc., Shire Development LLC (collectively, "Shire"), Cosmo Technologies Limited ("Cosmo"), and Nogra Pharma Limited ("Nogra") (collectively, "Plaintiffs") by their undersigned attomeys, for their Complaint against defendants Lupin Limited ("Lupin Ltd."), Lupin Pharmaceuticals Inc. ("LPI"), Lupin Inc. ("Lupin Inc."), and Lupin Atlantis Holdings SA ("Lupin Atlantis") (collectively "Lupin" or "Defendants") herein, allege as follows: NATURE OF THE ACTION l. This is a civil action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, involving United States Patent No.6,773,720 ("the '720 patent" or "the patent-in-suit"), attached hereto as Exhibit A. Case 8:15-cv-03437-GJH Document 1 Filed 11/10/15 Page 2 of 17 THE PARTIES 2. Plaintiff Shire Pharmaceutical Development Inc. is a corporation organized and existing under the laws of the state of Maryland, having its principal place of business at 1200 Morris Drive, Wayne, PA 19087. 3. Plaintiff Shire Development LLC is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at735 Chesterbrook Boulevard and 1200 Monis Drive, Wayne, Pennsylvania 19087. 4. Plaintiff Cosmo is a company organized and existing under the laws of Ireland, having its principal place of business at The Connolly Building, 42-43 Amiens Street, Dublin l, Ireland.
    [Show full text]
  • S.No. NAME of APPLICANT IEC NO. 1 IBM INDIA PRIVATE LIMITED 0797006486 2 MAGSONS EXPORTS 0588055743 3 SHAHI EXPORTS PRIVATE LIMI
    AEO T2 CERTIFIED ENTITIES S.No. NAME OF APPLICANT IEC NO. 1 IBM INDIA PRIVATE LIMITED 0797006486 2 MAGSONS EXPORTS 0588055743 3 SHAHI EXPORTS PRIVATE LIMITED 0588085481 4 NIPPON PAINT INDIA PRIVATE LIMITED 0505090619 5 DANFOSS INDIA PRIVATE LIMITED 0598045848 6 HONDA CARS INDIA LIMITED 0595049338 7 ANUPAM COLOURS PRIVATE LIMITED 0301012610 8 BOSCH AUTOMOTIVE ELECTRONICS INDIA PRIVATE LIMITED 0708022308 9 BOSCH LIMITED 0788000314 10 VELANKANI ELECTRONICS PRIVATE LIMITED 0715009729 11 FERRERO INDIA PRIVATE LIMITED 0707029953 12 SIEMENS LIMITED 0388070005 13 ENCUBE ETHICALS PRIVATE LIMITED 0396057993 14 NESTLE INDIA LIMITED 0588000531 15 3M INDIA LIMITED 0793012112 16 BIOLOGICAL E. LIMITED 0988000229 17 TOYOTA KIRLOSKAR MOTOR PRIVATE LIMITED 0797012451 18 MICROMAX INFORMATICS LIMITED 0503028665 19 3M ELECTRO & COMMUNICATION INDIA PRIVATE LIMITED 0493021329 20 DELL INTERNATIONAL SERVICES INDIA PRIVATE LIMITED 5196000691 21 EMBARKATION HEADQUARTERS 0307061281 22 USHODAYA ENTERPRISES PRIVATE LIMITED 0988001071 23 SAMSUNG INDIA ELECTRONICS PRIVATE LIMITED 0595032818 24 LENOVO INDIA PRIVATE LIMITED 0705001091 25 KUNDAN CARE PRODUCTS LIMTED 0504074008 26 INA BEARINGS INDIA PRIVATE LIMITED 3197032462 27 SCHNEIDER ELECTRIC INDIA PRIVATE LIMITED 0595007317 28 ORDNANCE FACTORY BOARD MUMBAI OFFICE MINISTRY OF DEFENCE 0307084434 29 JABIL CIRCUIT INDIA PRIVATE LIMITED 0302051139 30 KASTURI AND SONS LIMITED 0488007542 31 POPPYS KNITWEAR PRIVATE LIMITED 0488013011 32 ASTRA MICROWAVE PRODUCTS LIMITED 0991002300 33 CATERPILLAR INDIA PRIVATE LIMITED 0400023067
    [Show full text]
  • Lupin Limited: Rating Removed from Watch with Developing Implications
    November 20, 2019 Lupin Limited: Rating removed from watch with developing implications Summary of rating action Instrument* Previous Rated Amount Current Rated Amount Rating Action (Rs. crore) (Rs. crore) Short-term Fund-based 1,100.0 1,100.0 [ICRA]A1+, removed from Limits rating watch with developing implications Short-term Non-fund 400.0 400.0 [ICRA]A1+; removed from Based Limits rating watch with developing implications Total 1,500.0 1,500.0 *Instrument details are provided in Annexure-1 Material event Lupin Limited, on November 11, 2019, announced that it has approved the divestment of its entire equity interest (representing 99.82% of the issued and paid-up capital) of Kyowa Pharmaceutical Industry Co. Ltd (Kyowa) by way of sale of shares to Plutus Limited (an entity affiliated with Unison Capital partners) at an enterprise value (EV) of JPY 57,361 million (Rs.3702 crore), subject to necessary approvals including Japan Fair Trade Commission and shareholders of the company. The proposed transaction is an all cash-transaction, valued at EV/sales of 2 times and will result in post- tax net cash inflow of ~JPY 32,596 million (Rs. 2,104 crore). The transaction is expected to be concluded within FY2020. Impact of material event ICRA has a short-term rating of [ICRA]A1+ (pronounced ICRA A one plus) assigned to the Rs. 1,100-crore short-term fund- based limits and Rs. 400-crore short-term non-fund based limits. The rating has been removed from watch with developing implications. Rationale The removal of the rating watch factors in the expected strengthening of the credit profile of Lupin Limited, following the divestment of Kyowa (which accounted for 10.6% of consolidated operating income (OI) and 9.1% of OPBDITA of Lupin in FY2019), along with receipt of post-tax cash proceeds of JPY 32,596 million (Rs.2,104 crore).
    [Show full text]
  • United States Court of Appeals for the Federal Circuit ______
    Case: 16-1973 Document: 3-2 Page: 1 Filed: 07/20/2017 NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff-Appellant v. ZYDUS PHARMACEUTICALS USA, INC., CADILA HEALTHCARE, LIMITED, MYLAN INC., MYLAN PHARMACEUTICALS INC., TORRENT PHARMACEUTICALS LIMITED, TORRENT PHARMA INC., HETERO LABS LIMITED, AJANTA PHARMA LIMITED, AJANTA PHARMA USA INC., AUROBINDO PHARMA LTD., INTAS PHARMACEUTICALS LIMITED, ACCORD HEALTHCARE, INC., AUROBINDO PHARMA USA INC., AUROLIFE PHARMA LLC, LUPIN LIMITED, LUPIN ATLANTIS HOLDINGS S.A., LUPIN PHARMACEUTICALS, INC., ALEMBIC PHARMACEUTICALS LIMITED, AMNEAL PHARMACEUTICALS, LLC, AMNEAL PHARMACEUTICALS INDIA PVT. LTD., Defendants-Appellees ______________________ 2016-1962, 2016-1963, 2016-1964, 2016-1966, 2016-1968, 2016-1970, 2016-1971, 2016-1972, 2016-1973, 2016-1974, 2016-1975, 2016-1978 ______________________ Appeals from the United States District Court for the District of New Jersey in Nos. 1:14-cv-03168-JBS-KMW, Case: 16-1973 Document: 3-2 Page: 2 Filed: 07/20/2017 1:14-cv-04508-JBS-KMW, 1:14-cv-04671-JBS-KMW, 1:14- cv-05876-JBS-KMW, 1:14-cv-06158-JBS-KMW, 1:14-cv- 06890-JBS-KMW, 1:14-cv-07105-JBS-KMW, 1:14-cv- 07252-JBS-KMW, 1:14-cv-07405-JBS-KMW, 1:14-cv- 08074-JBS-KMW, 1:14-cv-08077-JBS-KMW, 1:15-cv- 01585-JBS-KMW, Chief Judge Jerome B. Simandle. ______________________ JUDGMENT ______________________ PAUL WILLIAM BROWNING, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington, DC, argued for plaintiff-appellant. Also represented by JAMES B. MONROE, CHARLES THOMAS COLLINS-CHASE, ERIC JAY FUES, ANDREA DENISE MAIN; JEFFREY ANDREW FREEMAN, Atlanta, GA.
    [Show full text]
  • In the United States District Court for the Eastern District of Michigan
    Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ABBOTT LABORATORIES and ) ABBOTT RESPIRATORY LLC, ) ) Plaintiffs, ) ) C.A. No. 2:10-cv-10656 v. ) ) SUN PHARMACEUTICAL INDUSTRIES, LTD. ) and SUN PHARMA GLOBAL FZE, ) ) Defendants. ) COMPLAINT Plaintiffs Abbott Laboratories and Abbott Respiratory LLC (collectively, “Abbott”), by their attorneys, hereby allege as follows: Nature of the Action This is an action for patent infringement of U.S. Patent Nos. 6,080,428 (“the ‘428 patent”) and 6,469,035 (“the ‘035 patent”), arising under the patent laws of the United States, Title 35, United States Code, 35 U.S.C. §§ 271 and 281. This action relates to Abbreviated New Drug Application (“ANDA”) No. 20-0484 filed by Sun Pharma Global FZE (“Sun FZE”) with the U.S. Food and Drug Administration (“FDA”) for approval to market 500 mg and 1000 mg niacin extended-release tablets that are generic versions of the 500 mg and 1000 mg strength versions of Abbott’s highly successful NIASPAN® drug product. Related Actions The present action is related to an identical patent infringement action pending before the United States District Court for the District of Delaware, Abbott Laboratories and Abbott Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 2 of 11 Respiratory, LLC v. Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceuticals, Inc. (C.A. 10-cv-112) (the “Delaware Sun Action”), pertaining to ANDA No. 20-0484 filed by Sun FZE for approval to market generic versions of Abbott’s 500 mg and 1000 mg strength NIASPAN® tablets.
    [Show full text]
  • Revision in Market Lot of Derivative Contracts on Individual Stocks
    Department : FUTURES & OPTIONS Download Ref No: NSE/FAOP/45895 Date : September 30, 2020 Circular Ref. No: 87/2020 All Members, Revision in Market Lot of Derivative Contracts on Individual Stocks In pursuance of SEBI guidelines for periodic revision of lot sizes for derivatives contracts specified in the SEBI circular CIR/MRD/DP/14/2015 dated July 13, 2015, the market lots of derivatives contracts shall be revised as follows: Sr. Underlying whose Derivative Count of Annexure No Effective date contract size shall be Underlying Number October 30, 2020 (for Nov 1 Revised Downwards 15 1 2020 & later expiries) 2 Revised Upwards 12 October 30, 2020 (for Jan 2 2021 & later expiries) 3 Unchanged 108 - 3 Revised Downwards but new October 30, 2020 (for Jan 4 lot size is not a multiple of old 1 4 2021 & later expiries) lot size To avoid operational complexities, in case of Annexure 2 and 4 above, following will be applicable: 1. Only the far month contract i.e. January 2021 expiry contracts will be revised for market lots. Contracts with maturity of November 2020 and December 2020 would continue to have the existing market lots. All subsequent contracts (i.e. January 2021 expiry and beyond) will have revised market lots. 2. The day spread order book will not be available for the combination contract of Dec 2020 – Jan 2021 expiry. For the purpose of the computation, the average of the closing price of the underlying has been taken for one month period of September 1st – September 30th 2020. This circular shall come into effect from October 30, 2020.
    [Show full text]
  • Cipla Limited
    Cipla Limited Registered Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: (9122) 2482 6000, Fax: (9122) 2482 6893, Email: [email protected], Website: www.cipla.com Corporate Identity Number: L24239MH1935PLC002380 Annexure to the Board’s Report Particulars of employee remuneration for the financial year ended 31st March, 2019 As required under section 197(12) of the Companies Act, 2013, read with rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Employed throughout the year Name Designation Qualification Experience Age Date of Last employment Remuneration (in years) (in years) Employment (Rs.) Abhay Kumar Chief Talent Officer Master of Arts / 17 53 3/10/2016 Piramal Pharma 15,034,298.00 Srivastava Master of Personal Solutions Management Ademola Olukayode Head - Quality Doctorate / MPH / B. 17 48 20/6/2018 US FOOD AND DRUG 17,982,961.00 Daramola Compliance & Tech. ADMINISTRATION Sustainability (US FDA) Ajay Luharuka Head Finance - IPD, B.com,MMS,CFA 23 46 11/7/1996 NIIT Limited 11,922,994.00 API, Specialty & Global Respi Aliakbar Rangwala Senior Business Head M. Sc. / B. Sc. 19 42 19/1/2009 NA 10,677,779.00 - Chronic & Emerging - India Business Alpana Vartak Head - Talent MBA (HR) / B. Sc. 15 41 8/1/2018 Coco - Cola 10,312,782.00 Acquisition Company Anil Kartha Site Head - Bsc, Bpharm 28 56 27/5/1991 Vysali 12,525,338.00 Patalganga - Pharmaceuticals Formulations Anindya Kumar Shee Head - Organization B. Tech. / MBA 18 48 14/1/2016 Reliance Industries 11,084,298.00 Development Ltd.
    [Show full text]
  • DR REDDYS LABORATORIES LTD Form 20-F Filed 2020-06-15
    SECURITIES AND EXCHANGE COMMISSION FORM 20-F Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Filing Date: 2020-06-15 | Period of Report: 2020-03-31 SEC Accession No. 0001575872-20-000145 (HTML Version on secdatabase.com) FILER DR REDDYS LABORATORIES LTD Mailing Address Business Address 8-2-337, ROAD NO.3 8-2-337, ROAD NO.3 CIK:1135951| IRS No.: 000000000 | Fiscal Year End: 0331 BANJARA HILLS BANJARA HILLS Type: 20-F | Act: 34 | File No.: 001-15182 | Film No.: 20963158 HYDERABAD K7 500-034 HYDERABAD K7 500-034 SIC: 2834 Pharmaceutical preparations 91 40 49002900 Copyright © 2020 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT ¨ OF 1934 OR þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ¨ 1934 Commission File Number: 1-15182 DR. REDDY’S LABORATORIES LIMITED (Exact name of Registrant as specified in its charter) Not Applicable TELANGANA, INDIA (Translation of Registrant’s name (Jurisdiction of incorporation or into English) organization) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive offices) Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, [email protected] 8-2-337, Road No.
    [Show full text]
  • List of Nodal Officer
    List of Nodal Officer Designa S.No tion of Phone (With Company Name EMAIL_ID_COMPANY FIRST_NAME MIDDLE_NAME LAST_NAME Line I Line II CITY PIN Code EMAIL_ID . Nodal STD/ISD) Officer 1 VIPUL LIMITED [email protected] PUNIT BERIWALA DIRT Vipul TechSquare, Golf Course Road, Sector-43, Gurgaon 122009 01244065500 [email protected] 2 ORIENT PAPER AND INDUSTRIES LTD. [email protected] RAM PRASAD DUTTA CSEC BIRLA BUILDING, 9TH FLOOR, 9/1, R. N. MUKHERJEE ROAD KOLKATA 700001 03340823700 [email protected] COAL INDIA LIMITED, Coal Bhawan, AF-III, 3rd Floor CORE-2,Action Area-1A, 3 COAL INDIA LTD GOVT OF INDIA UNDERTAKING [email protected] MAHADEVAN VISWANATHAN CSEC Rajarhat, Kolkata 700156 03323246526 [email protected] PREMISES NO-04-MAR New Town, MULTI COMMODITY EXCHANGE OF INDIA Exchange Square, Suren Road, 4 [email protected] AJAY PURI CSEC Multi Commodity Exchange of India Limited Mumbai 400093 0226718888 [email protected] LIMITED Chakala, Andheri (East), 5 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 6 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 7 NECTAR LIFE SCIENCES LIMITED [email protected] SUKRITI SAINI CSEC NECTAR LIFESCIENCES LIMITED SCO 38-39, SECTOR 9-D CHANDIGARH 160009 01723047759 [email protected] 8 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 9 SMIFS CAPITAL MARKETS LTD.
    [Show full text]
  • Dr. Reddy's Laboratories . Company  Dr
    BY SHIVAM RAJPUT Dr. Reddy's Laboratories . Company Dr. Reddy's Laboratories Ltd, is a pharmaceutical company based in Hyderabad, Andhra Pradesh, India. Headquarters: HYDERABAD, india Founder: Kallam Anji Reddy Founded: 1984 Company Profile The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed. They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". Reddy's sold the joint venture to the Kremlin-friendly Sistema group. In 1993, Reddy's entered into a joint venture in the Middle East and created two formulation units there and in Russia. Reddy's exported bulk drugs to these formulation units, which then converted them into finished products. In 1994, Reddy's started targeting the US generic market by building state of art manufacturing facility. In March 2002 Dr Reddy’s acquired BHM Laboratories ,Beverley, and its wholly owned subsidiary meridian health care, EURO 14.81 million. Recently Dr. Reddy’s entered into R & D and Commercialization agreement with Argenta Discovery Ltd, for the treatment of COPD. In march 2006 Dr.reddy’s acquired Betapharm arzneimittel GmbH from 3i for euro 480 million. Betapharm employs more than 350 personnel and its turnover amounts to Euro 186 million . It commands a share of 3.5 % in the German pharmaceutical market. In 2006 – 2007, Dr Reddy’s generated a revenue of EUR 80.5 million from Europe , which accounted for 18% of the company’s total revenue.
    [Show full text]
  • S.No. Scrip Name Symbol Series Leverage (In Times) 1 MARICO
    SCRIPS AVAILABLE FOR INTRADAY WITH LEVERAGES PROVIDED ON THEM Leverage Scrip Name Symbol Series (in times) S.No. 1 MARICO LIMITED MARICO 7.61 2 DABUR INDIA LIMITED DABUR 7.92 3 HINDUSTAN UNILEVER LIMITED HINDUNILVR 7.48 4 COLGATE PALMOLIVE (INDIA) LIMITED COLPAL 7.48 5 NESTLE INDIA LIMITED NESTLEIND 7.39 6 Alkem Laboratories Limited ALKEM 6.91 7 TATA CONSULTANCY SERVICES LIMITED TCS 7.24 8 DR. REDDY'S LABORATORIES LIMITED DRREDDY 6.54 9 PIDILITE INDUSTRIES LIMITED PIDILITIND 7.07 10 GODREJ CONSUMER PRODUCTS LIMITED GODREJCP 5.79 11 POWER GRID CORPORATION OF INDIA LIMITED POWERGRID 6.46 12 ACC LIMITED ACC 6.61 13 NTPC LIMITED NTPC 6.64 14 ITC LIMITED ITC 7.05 15 ASIAN PAINTS LIMITED ASIANPAINT 6.52 16 BRITANNIA INDUSTRIES LIMITED BRITANNIA 6.98 17 BERGER PAINTS (I) LIMITED BERGEPAINT 6.78 18 EXIDE INDUSTRIES LIMITED EXIDEIND 6.89 19 HDFC BANK LIMITED HDFCBANK 6.63 20 DIVI'S LABORATORIES LIMITED DIVISLAB 6.69 21 MRF LIMITED MRF 6.73 22 INDIAN OIL CORPORATION LIMITED IOC 6.49 23 BAJAJ AUTO LIMITED BAJAJ-AUTO 6.64 24 SIEMENS LIMITED SIEMENS 6.40 25 THE RAMCO CEMENTS LIMITED RAMCOCEM 6.23 26 TORRENT POWER LIMITED TORNTPOWER 6.10 27 UNITED BREWERIES LIMITED UBL 6.16 28 INFOSYS LIMITED INFY 6.82 29 CIPLA LIMITED CIPLA 6.52 30 Pfizer Limited PFIZER 6.41 31 PETRONET LNG LIMITED PETRONET 6.45 32 UNITED SPIRITS LIMITED MCDOWELL-N 6.24 33 CADILA HEALTHCARE LIMITED CADILAHC 5.97 34 WIPRO LIMITED WIPRO 6.10 35 SUN PHARMACEUTICAL INDUSTRIES LIMITED SUNPHARMA 6.18 36 BATA INDIA LIMITED BATAINDIA 6.44 37 LARSEN & TOUBRO LIMITED LT 6.38 38 ULTRATECH CEMENT
    [Show full text]
  • LUPIN LIMITED Registered Office: 3Rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400 055
    LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400 055. Tel:+91 22 6640 2323 Ext: 2402/2403 E-mail: [email protected]; Website: www.lupin.com Corporate Identity Number: L24100MH1983PLC029442 NOTICE OF POSTAL BALLOT Dear Members, Notice pursuant to Section 110 of the Companies Act, 2013 Notice is hereby given pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013 (Act) read with Rule 22 of the Companies (Management & Administration) Rules, 2014, as amended by the Companies (Management & Administration) Amendment Rules, 2015 and other applicable laws and Regulations that Ordinary Resolutions are proposed to be passed by the Members of the Company through Postal Ballot for the following matters: - 1. To approve the appointment of Mr. K. B. S. Anand (DIN: 03518282), as an Independent Director of the Company, for a period of five years, effective August 12, 2020; 2. To approve the appointment of Dr. Punita Kumar-Sinha (DIN: 05229262), as an Independent Director of the Company, for a period of five years, effective August 12, 2020; 3. To approve the appointment of Mr. Robert Funsten (DIN: 08950420), as an Independent Director of the Company, for a period of six months, effective November 10, 2020; and 4. To approve the appointment of Mr. Mark D. McDade (DIN: 09037255), as an Independent Director of the Company, for a period of five years, effective January 28, 2021. The proposed Resolutions and Explanatory Statements under Section 102(2) of the Act, stating material facts are annexed to this Notice for your consideration.
    [Show full text]